701294-99-7Relevant academic research and scientific papers
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARα selective activators
Li, Zhibin,Liao, Chenzhong,Ko, Ben C. B.,Shan, Song,Tong, Edith H. Y.,Yin, Zihui,Pan, Desi,Wong, Vincent K. W.,Shi, Leming,Ning, Zhi-Qiang,Hu, Weiming,Zhou, Jiaju,Chung, Stephen S. M.,Lu, Xian-Ping
, p. 3507 - 3511 (2004)
Lipid accumulation in nonadipose tissues is increasingly linked to the development of type 2 diabetes in obese individuals. We report here the design, synthesis, and evaluation of a series of novel PPARα selective activators containing 1,3-dicarbonyl moie
New PPARγ ligands based on barbituric acid: Virtual screening, synthesis and receptor binding studies
Sundriyal, Sandeep,Viswanad, Bhoomi,Ramarao, Poduri,Chakraborti, Asit K.,Bharatam, Prasad V.
scheme or table, p. 4959 - 4962 (2009/05/30)
A new series of PPARγ ligands based on barbituric acid (BA) has been designed employing virtual screening and molecular docking approach. To validate the computational approach, designed molecules were synthesized and evaluated in in vitro radioligand bin
NONCYCLIC 1,3-DICARBONYL COMPOUNDS AS DUAL PPAR AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY
-
Page 22, (2008/06/13)
Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R', R2, R3, R4, R5, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPARgamma and RXRIPPARalpha heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders.
